Detalhe da pesquisa
1.
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10419): 2295-2306, 2023 12 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37931632
2.
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
Oncologist
; 27(3): e286-e293, 2022 03 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35274718
3.
Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.
Lancet Oncol
; 22(2): 190-197, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33450184
4.
The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data.
Qual Life Res
; 30(2): 445-454, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32851601
5.
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
Oncologist
; 24(7): e510-e517, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30478189
6.
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.
Oncologist
; 24(7): e501-e509, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30952820
7.
Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
Mol Carcinog
; 58(11): 1960-1973, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31355511
8.
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Breast Cancer Res
; 19(1): 54, 2017 05 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28464908
9.
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
Eur Respir J
; 49(3)2017 03.
Artigo
Inglês
| MEDLINE | ID: mdl-28298401
10.
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
Breast Cancer Res Treat
; 157(1): 109-16, 2016 05.
Artigo
Inglês
| MEDLINE | ID: mdl-27116183
11.
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Lancet Oncol
; 15(12): 1379-88, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25439692
12.
Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence.
Curr Oncol
; 31(4): 1947-1960, 2024 04 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38668049
13.
Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma.
Clin Lung Cancer
; 2024 Apr 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38825405
14.
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial.
J Clin Oncol
; : JCO2400720, 2024 Jun 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38843488
15.
Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 24(1): 40-50, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36270866
16.
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Nat Med
; 29(10): 2559-2569, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37814061
17.
Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence.
Cancer Treat Res Commun
; 37: 100774, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37979334
18.
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
JTO Clin Res Rep
; 4(10): 100562, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37744308
19.
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
JAMA Netw Open
; 6(7): e2325332, 2023 07 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37490292
20.
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
J Thorac Oncol
; 18(6): 813-819, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36841541